Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Drug Updates

Subcategories:AnalgesicsBiologics/DMARDs

More Than a Third of U.S. Adults Prescribed Opioids in 2015

Andrew M. Seaman  |  

(Reuters Health)—The U.S. needs to curb excessive opioid prescribing and improve access to pain management techniques, suggests a new government study. Researchers found that more than one third of U.S. adults were prescribed the medications in 2015 and many also misused the drugs. “A very large proportion and large number of adults use these medications…

U.S. House Panel Spotlights Use of FDA Rules to Slow Generic Drugs

Diane Bartz  |  

WASHINGTON (Reuters)—Republican and Democratic lawmakers on Thursday discussed ways to prevent drugmakers from using rules developed to safeguard patients to instead block the sale of cheaper medicines. The focus at a hearing, held by members of the House Judiciary Committee’s antitrust subcommittee, was on the use by some brand name drug companies of a U.S….

As Drug Prices Drop, Generics Makers Fight Back with Deals

Carl O'Donnell  |  

NEW YORK (Reuters)—Generic drug makers are turning to mergers and acquisitions to shield themselves against a concerted effort by U.S. regulators to crack down on steep drug prices. Impax Laboratories Inc, Perrigo Company Plc and Alvogen Inc have been talking to advisers about strategic options for their generics businesses, ranging from acquisitions to increase scale…

U.S. Senator Expands Opioid Probe to Distributors, Drugmakers

Reuters Staff  |  

(Reuters)—U.S. Democratic Senator Claire McCaskill on Thursday expanded an investigation into the causes of the opioid crisis plaguing the country, seeking information from four more drugmakers and three drug distributors. The top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee is focusing on the distribution of opioids and the efforts companies made to…

Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA

  |  

Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…

Allopurinol Appears More Renoprotective than Febuxostat in Older Adults

Reuters Staff  |  

NEW YORK (Reuters Health)—The renal protective effect of allopurinol appears to differ from that of febuxostat in the elderly, according to new research. The study, of a nationally representative sample of Medicare patients, showed that allopurinol was associated with a greater reduction in the risk of incident kidney disease, report the authors online July 13…

Drug Tapering: Studies Point to Success in Some Patients

  |  

Highlights from the 2017 EULAR Congress MADRID—Scores on the Health Assessment Questionnaire for Rheumatoid Arthritis (HAQ) and C-reactive protein (CRP) levels were independent predictors of whether patients could be tapered successfully from a TNF inhibitor after having reached remission of their RA, according to findings presented in a session at the Annual European Congress of…